Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

LONDON, UK, 11 February 2025, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and ...

This is all to say that my experience with Civilization 7 during the review period was mostly long play sessions of obsession ...

1 Day SNDA -0.26% DJIA 0.65% Russell 2K -1.03% Health Care/Life Sciences -1.12% ...

Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral HIF-2α inhibitor, Welireg (belzutifan), for a new indication. The sNDA is ...

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience. To access our Live RNS you must confirm you are a private ...

Buy SNDA near 20.28 target 26.36 stop loss @ 20.22 Details The technical summary data tells us to buy SNDA near 20.28 with an upside target of 26.36. This data also tells us to set a stop loss @ 20.22 ...

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

Want to apply for Canada PR? The country is set to introduce four new permanent residency (PR) pathways in 2025, even as the government plans to reduce its PR targets from 485,000 to 465,000, ...

TITUSVILLE, NJ, USA I January 21, 2025 I Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO ® ...

2020, Book Chapter: "In a time of increasing divisiveness in politics and society, there is a desperate need for leaders to bring people together and leverage the power of diversity and inclusion.